Insmed Incorporated
INSMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeInsmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. Valued at $23.29B, INSM is a large-cap name in its sector. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Market Cap
$23.29B
Beta
0.78
P/E (TTM)
—
P/E (Fwd)
1060.70
EPS (TTM)
$-5.64
EPS (Fwd)
$0.10
ROE
-294.5%
ROA
-31.1%
Cash
$1.22B
Total Debt
$742.5M
Free CF
-$606.2M
52W Change
3.2%
Annual Financials
Cash vs Debt
With $1.22B in cash and $742.5M in debt, INSM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$606.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -294.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $245.4M (2022) to $606.4M (2025), reflecting a 147% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing INSM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.